Nicolas Girard, MD, on the Rationale and Design of the Phase 3 CheckMate 816 Trial in Resectable NSCLC

In an interview with CancerNetwork®, Nicolas Girard, MD, discussed the rationale for assessing nivolumab and chemotherapy in resectable non–small cell lung cancer and the design of the phase 3 CheckMate 816 trial.

In an interview with CancerNetwork® during the American Association for Cancer Research (AACR) 2022 Annual Meeting, Nicolas Girard, MD, professor of respiratory medicine at Versailles Saint Quentin University and head of Curie-Montsouris Thorax Institute of Institut Curie in Paris, highlighted the rationale for assessing nivolumab (Opdivo) and chemotherapy in resectable non–small cell lung cancer.

In addition to highlighting previous findings with the combination, he detailed the design of the phase 3 CheckMate 816 trial (NCT02998528), which assessed the regimen vs chemotherapy alone in the aforementioned patient population.

Transcript:

We have many phase 2 studies that demonstrated the benefit of neoadjuvant immunotherapy with immune checkpoint inhibitors targeting PD-1 or PD-L1, especially in terms of pathological response. [As these were] only phase 2 studies, it has always been difficult to know whether this is a true benefit compared with the standard of care, which historically has been chemotherapy. In this study, Checkmate 816, we randomized 358 patients to a combination of nivolumab plus chemotherapy vs chemotherapy alone.

[The trial had] 2 primary end points [including] pathological complete response and event-free survival. The advantage of the neoadjuvant approach is to include all the patients eligible for surgical resection of the tumor. With that, we treated the patients for 3 cycles before surgery and then surgery was performed in the majority of patients—83.2% in the experimental [arm] and 75.4% in the control [arm].

Reference

Forde PM, Spicer J, Lu S, et al. CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. Published online April 11, 2022. doi:10.1056/NEJMoa2202170

Related Videos
An expert from Yale School of Medicine discusses how the approval of adjuvant pembrolizumab expands treatment to include patients with IB, II, III, and IIIA resected, early-stage, non–small cell lung cancer regardless of PD-L1 expression.
Alexander Spira, MD, PhD, FACP, of the Virginia Cancer Specialists, discusses how the FDA approval of adagrasib for KRAS G12C–mutated non–small cell lung cancer can provide benefit for this patient population.
Pooling data with other radiation trials, looking more closely at central non-small cell lung cancer, and exploring secondary outcomes represent the next steps in terms of analyzing stereotactic body radiation (SBRT) vs conventional hypofractionated radiotherapy (CRT), according to Anand Swaminath, MD.
Anand Swaminath, MD, reviews the design of the phase 3 LUSTRE trial comparing a 3-week conventional radiotherapy regimen with stereotactic body radiotherapy among patients with stage I medically inoperable non-small cell lung cancer.
Stereotactic body radiation therapy yielded numerical improvements in terms of local control compared with conventional hypofractionated radiotherapy among patients with stage I medically inoperable non-small cell lung cancer, according to findings from the phase 3 LUSTRE trial.
Data from the phase 3 LUSTRE trial indicated that stereotactic body radiotherapy is a safe and effective alternative to conventional radiation for use in patients with stage I medically-inoperable non-small lung cancer, according to an expert from Juravinski Cancer Centre in Canada.
Hossein Borghaei, DO, MS, discussed where investigators may drive future research following the phase 2 Lung-MAP trial examining pembrolizumab and ramucirumab in previously treated advanced non–small cell lung cancer.
Hossein Borghaei, DO, MS, highlights data that read out of the phase 2 Lung-MAP trial, assessing ramucirumab/pembrolizumab in previously treated advanced non–small cell lung cancer.
Related Content